Incentivising Medicine Development for Chronic Diseases – Workshop Report
This CIRS multi-stakeholder workshop examined strategies for incentivising the development of medicines for common chronic diseases.
Regulatory performance of ML3 African NMRAs – Owusu-Asante 2025
Background The World Health Organization (WHO) developed the WHO Global Benchmarking Tool (GBT) to assess and benchmark the drug regulatory systems and practices in national medicines regulatory authorities (NMRAs). [...]
Contribution of the ECOWAS region to the African Medicines Agency
“This book is a must-read for all those with interest in medicines regulation in Africa… It provides timely expert information for consideration and possible adoption during the operationalisation of [...]
CIRS RD Briefing 103 – Review of HTA outcomes and timelines in Australia, Canada, Europe and the UK, 2020-2024
This R&D Briefing presents findings from HTADock, an ongoing CIRS metrics study that collects publicly available data on new active substances (NASs) appraised by 12 HTA agencies in Australia [...]
Incentivising Medicine Development for Chronic Diseases – Workshop Synopsis
This CIRS multi-stakeholder workshop examined strategies for incentivising the development of medicines for common chronic diseases.
How are international regulatory organisations shaping global pharmaceutical policy? Dangy-Caye et al 2025
We’re pleased to share our latest publication in Frontiers in Medicine, developed in collaboration with Sanofi, exploring how international regulatory organisations are shaping global pharmaceutical policy. Data from our [...]
September 2025 Newsletter
Take a look at our latest newsletter, which shares updates on key research activities and publications in the third quarter of 2025. Download newsletter
Evaluation of good review practices at FDA Ghana – Owusu-Asante 2025
The aim of this study was to assess the good review practices (GRevPs) of the Food and Drugs Authority (FDA) Ghana in order to identify opportunities for improvement. Reviewers [...]
CIRS RD Briefing 102 – Tracking Availability in China of Medicines Approved in Six Key Global Markets
All approved medicines have been rigorously assessed by regulatory authorities to ensure their benefits outweigh the risks. Today, pharmaceutical companies are increasingly focused on integrated global drug development strategies, [...]
Enhancing Development Strategies Through Early HTA Scientific Advice – Wang 2025
Introduction Early health technology assessment (HTA) advice provides value to pharmaceutical companies during drug development by identifying potential data gaps, refining study designs, and improving understanding of HTA agencies’ [...]